

Mei Sheng Duh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/17147/publications.pdf>

Version: 2024-02-01

220
papers

2,713
citations

236833

25
h-index

265120

42
g-index

221
all docs

221
docs citations

221
times ranked

3857
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015â€“2020. <i>Clinical Cancer Research</i> , 2022, 28, 27-35.	3.2	22
2	Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe. <i>Crohn's & Colitis</i> 360, 2022, 4, .	0.5	2
3	Real-world Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Newly Treated Korean Patients With Asthma: A Retrospective Cohort Study. <i>Allergy, Asthma and Immunology Research</i> , 2022, 14, 220.	1.1	3
4	Literature Review of Fatigue Scales and Association with Clinically Meaningful Improvements in Outcomes Among Patients With and Without Paroxysmal Nocturnal Hemoglobinuria. <i>Advances in Therapy</i> , 2022, 39, 1959-1975.	1.3	2
5	Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation. <i>International Journal of COPD</i> , 2022, Volume 17, 491-504.	0.9	11
6	Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study. <i>Respiratory Medicine</i> , 2022, 197, 106807.	1.3	13
7	Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation. <i>Journal of Medical Economics</i> , 2022, 25, 367-380.	1.0	4
8	Estimating the US pericarditis prevalence using national health encounter surveillance databases. <i>Current Medical Research and Opinion</i> , 2022, , 1-5.	0.9	0
9	Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population. <i>ClinicoEconomics and Outcomes Research</i> , 2022, Volume 14, 357-369.	0.7	9
10	The Acute Effects of Azithromycin Use on Cardiovascular Mortality as Compared with <scp>Amoxicillinâ€Clavulanate</scp> in United States Veterans. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, , .	0.9	0
11	Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA. <i>Child's Nervous System</i> , 2022, , .	0.6	3
12	Retrospective study to examine prognostic value of c-reactive protein (CRP) in patients with surgically resected non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e20569-e20569.	0.8	0
13	Burden of Recurrent Pericarditis on Health-Related Quality of Life. <i>American Journal of Cardiology</i> , 2021, 141, 113-119.	0.7	8
14	Realâ€world outcomes of patients with locally advanced or metastatic epithelioid sarcoma. <i>Cancer</i> , 2021, 127, 1311-1317.	2.0	8
15	Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA. <i>Targeted Oncology</i> , 2021, 16, 85-94.	1.7	2
16	Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 210-219.	2.0	11
17	Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs. <i>Journal of Asthma</i> , 2021, 58, 102-111.	0.9	31
18	Treatment patterns, healthcare resource utilization, and costs of patients diagnosed with primary mediastinal B-cell lymphoma in the United States. <i>Journal of Medical Economics</i> , 2021, 24, 469-478.	1.0	1

#	ARTICLE	IF	CITATIONS
19	Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S. <i>Oncologist</i> , 2021, 26, e817-e826.	1.9	9
20	Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease. <i>Pulmonary Therapy</i> , 2021, 7, 203-219.	1.1	2
21	Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities. <i>International Journal of COPD</i> , 2021, Volume 16, 1149-1161.	0.9	5
22	Real-world impact of antiepileptic drug combinations with versus without perampanel on healthcare resource utilization in patients with epilepsy in the United States. <i>Epilepsy and Behavior</i> , 2021, 118, 107927.	0.9	3
23	Health-related quality of life (HRQoL) among pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) in the United States (U.S.). <i>Journal of Clinical Oncology</i> , 2021, 39, 10042-10042.	0.8	0
24	Development and Validation of a Healthcare Utilization-Based Algorithm to Identify Acute Exacerbations of Chronic Obstructive Pulmonary Disease. <i>International Journal of COPD</i> , 2021, Volume 16, 1687-1698.	0.9	1
25	RARE-06. CLINICAL BURDEN AMONG PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND PLEXIFORM NEUROFIBROMA (PN) IN THE UNITED STATES (US). <i>Neuro-Oncology</i> , 2021, 23, i41-i42.	0.6	0
26	Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study. <i>BMC Pulmonary Medicine</i> , 2021, 21, 253.	0.8	6
27	Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors. <i>Advances in Therapy</i> , 2021, 38, 4520-4540.	1.3	32
28	Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population. <i>Advances in Therapy</i> , 2021, 38, 4461-4479.	1.3	16
29	Compliance With Cannabis Act Regulations Regarding Online Promotion Among Canadian Commercial Cannabis-Licensed Firms. <i>JAMA Network Open</i> , 2021, 4, e2116551.	2.8	13
30	Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan. <i>Frontiers in Oncology</i> , 2021, 11, 678070.	1.3	6
31	Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 480-490.	0.9	11
32	Symptom control in patients with asthma using inhaled corticosteroids/long-acting β_2 -agonists (fluticasone furoate/vilanterol or budesonide/formoterol) in the US: a retrospective matched cohort study. <i>Journal of Asthma</i> , 2021, , 1-14.	0.9	3
33	Disease and Economic Burden Associated with Recurrent Pericarditis in a Privately Insured United States Population. <i>Advances in Therapy</i> , 2021, 38, 5127-5143.	1.3	5
34	Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center. <i>Oncologist</i> , 2021, 26, e2161-e2169.	1.9	8
35	Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021, 17, 2907-2921.	1.1	12
36	Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison. <i>Current Medical Research and Opinion</i> , 2021, 37, 1913-1923.	0.9	13

#	ARTICLE	IF	CITATIONS
37	Increased Health Care Resource Utilization and Costs Associated with Herpes Zoster Among Patients Aged ≥50 Years with Chronic Obstructive Pulmonary Disease in the United States. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2021, 8, 502-516.	0.5	4
38	Retrospective analysis of adherence to HIV treatment and healthcare utilization in a commercially insured population. <i>Journal of Medical Economics</i> , 2021, 24, 1204-1211.	1.0	4
39	Real-World Ravulizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population. <i>Blood</i> , 2021, 138, 4999-4999.	0.6	0
40	Treatment Patterns and Outcomes of Patients with Double-Class Refractory or Triple-Class Refractory Multiple Myeloma: A Retrospective US Electronic Health Record Database Study. <i>Blood</i> , 2021, 138, 2705-2705.	0.6	2
41	Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study. <i>Blood</i> , 2021, 138, 3646-3646.	0.6	0
42	Time and Personnel Costs Associated with Adverse Event (AE) Management Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Acalabrutinib, Ibrutinib, or Venetoclax. <i>Blood</i> , 2021, 138, 2999-2999.	0.6	0
43	QOLP-02. HEALTH-RELATED QUALITY OF LIFE (HRQOL) AMONG PEDIATRIC PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND PLEXIFORM NEUROFIBROMA (PN) IN THE UNITED STATES: PERSPECTIVES OF THE PATIENTS AND CAREGIVERS. <i>Neuro-Oncology</i> , 2021, 23, vi182-vi183.	0.6	0
44	853. Real-World Persistency of Patients Receiving Tenofovir-Based Pre-Exposure Prophylaxis for the Prevention of HIV Infection in the US. <i>Open Forum Infectious Diseases</i> , 2021, 8, S516-S517.	0.4	0
45	Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the National Health Insurance Review and Assessment Service database. <i>BMC Urology</i> , 2021, 21, 178.	0.6	0
46	Development of risk models for major adverse chronic renal outcomes among patients with type 2 diabetes mellitus using insurance claims: a retrospective observational study. <i>Current Medical Research and Opinion</i> , 2020, 36, 219-227.	0.9	7
47	Treatment patterns and deep molecular response in chronic phase “ chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study. <i>Leukemia and Lymphoma</i> , 2020, 61, 98-107.	0.6	11
48	Determinants of Meningococcal ACWY vaccination in adolescents in the US: completion and compliance with the CDC recommendations. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 176-188.	1.4	8
49	<p></p>Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6607-6614.	0.9	8
50	MEDICATION ADHERENCE AND COPD-RELATED COSTS AMONG PATIENTS WITH COPD TREATED WITH UMECLIDINIUM/VILANTEROL (UMEC/VI) VS TIOTROPIUM (TIO). <i>Chest</i> , 2020, 158, A1720-A1721.	0.4	1
51	<p>Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9713-9719.	0.9	3
52	Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer. <i>PLoS ONE</i> , 2020, 15, e0230444.	1.1	4
53	Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study. <i>Hereditary Cancer in Clinical Practice</i> , 2020, 18, 13.	0.6	0
54	Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database. <i>Dermatology and Therapy</i> , 2020, 10, 791-806.	1.4	22

#	ARTICLE	IF	CITATIONS
55	Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study. <i>Annals of Hematology</i> , 2020, 99, 743-752.	0.8	1
56	<p>Direct and Indirect Costs of Infectious Conjunctivitis in a Commercially Insured Population in the United States</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 377-387.	0.9	10
57	Retrospective analysis of comorbidities and treatment burden among patients with HIV infection in a US Medicaid population. <i>Current Medical Research and Opinion</i> , 2020, 36, 781-788.	0.9	14
58	EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. <i>BMC Cancer</i> , 2020, 20, 356.	1.1	33
59	Role of real-world evidence for oncology product registration in the United States: A review of approvals by the U.S. Food and Drug Administration from 2015 to 2019.. <i>Journal of Clinical Oncology</i> , 2020, 38, e14130-e14130.	0.8	2
60	Management of pyrexia in metastatic melanoma patients: A real-world clinical experience survey study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e22102-e22102.	0.8	1
61	Real-world utilization of radium-223 (Ra-223) for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A U.S. tertiary oncology center analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 223-223.	0.8	0
62	Abstract 307: Real-world Clinical Characteristics and Recurrence Burden of Patients Diagnosed With Recurrent Pericarditis in The United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, .	0.9	0
63	Abstract 248: Recurrence Burden in Recurrent Pericarditis: A US-based Retrospective Study of Administrative Healthcare Claims. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, .	0.9	0
64	A multicenter chart review study of patients with metastatic pancreatic ductal adenocarcinoma receiving liposomal irinotecan after gemcitabine-based therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16733-e16733.	0.8	0
65	Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19345-e19345.	0.8	0
66	Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting.. <i>Journal of Clinical Oncology</i> , 2020, 38, 281-281.	0.8	1
67	Real-world evidence for U.S. Food and Drug Administration-approved oncology products, 2015 to 2020.. <i>Journal of Clinical Oncology</i> , 2020, 38, 280-280.	0.8	0
68	Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Previously Treated with Eculizumab: A Matching-Adjusted Indirect Comparison. <i>Blood</i> , 2020, 136, 37-38.	0.6	0
69	Real-World Treatment Patterns and Healthcare Resource Utilization (HRLU) of Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population. <i>Blood</i> , 2020, 136, 15-16.	0.6	1
70	Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population. <i>Blood</i> , 2020, 136, 13-13.	0.6	2
71	Title is missing!. , 2020, 15, e0230444.		0
72	Title is missing!. , 2020, 15, e0230444.		0

#	ARTICLE	IF	CITATIONS
73	Title is missing!. , 2020, 15, e0230444.		0
74	Title is missing!. , 2020, 15, e0230444.		0
75	Effects of systemic corticosteroids on blood eosinophil counts in asthma: real-world data. Journal of Asthma, 2019, 56, 808-815.	0.9	33
76	The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors. Lung Cancer, 2019, 138, 131-138.	0.9	6
77	<p>Characterizing Real-World Use Of Tiotropium In Asthma In The USA</p>. Journal of Asthma and Allergy, 2019, Volume 12, 309-321.	1.5	20
78	Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex. Epilepsia Open, 2019, 4, 581-592.	1.3	19
79	Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive. Melanoma Research, 2019, 29, 301-310.	0.6	7
80	Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis. American Journal of Hematology, 2019, 94, E96-E99.	2.0	5
81	A Budget Impact Analysis of the Introduction of Copanlisib for Treatment of Relapsed Follicular Lymphoma in the United States. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 437-446.	0.5	5
82	Development of a classifier to identify patients with probable Lennox-Gastaut syndrome in health insurance claims databases via random forest methodology. Current Medical Research and Opinion, 2019, 35, 1415-1420.	0.9	4
83	<p>Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population</p>. International Journal of COPD, 2019, Volume 14, 343-352.	0.9	58
84	2512. Decreasing Adherence to Antiretroviral Therapy over 4 Years of Follow-up in a Commercially-Insured Population of Patients with HIV. Open Forum Infectious Diseases, 2019, 6, S872-S872.	0.4	1
85	Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. Oncologist, 2019, 24, 1066-1075.	1.9	10
86	Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. Oncologist, 2019, 24, 1056-1065.	1.9	8
87	Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study. American Journal of Hematology, 2019, 94, 200-208.	2.0	22
88	Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study. Future Oncology, 2019, 15, 359-370.	1.1	11
89	An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records. Journal of Diabetes and Its Complications, 2019, 33, 140-147.	1.2	7
90	Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) in patients with metastatic colorectal cancer (mCRC): A single institution retrospective study.. Journal of Clinical Oncology, 2019, 37, 592-592.	0.8	3

#	ARTICLE	IF	CITATIONS
91	Economic burden of select adverse events (AEs) in patients (Pts) with advanced urothelial cancer (aUC) treated with first-line (1L) systemic therapy.. Journal of Clinical Oncology, 2019, 37, 363-363.	0.8	1
92	Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.. Journal of Clinical Oncology, 2019, 37, 610-610.	0.8	1
93	Comparison of real-world treatment patterns, persistence, healthcare resource utilization (HRU) and costs between octreotide and lanreotide for the treatment of neuroendocrine tumors (NET).. Journal of Clinical Oncology, 2019, 37, 105-105.	0.8	0
94	Factors associated with receipt and overall survival of concurrent chemoradiotherapy versus single modality therapy in unresectable stage III NSCLC.. Journal of Clinical Oncology, 2019, 37, e18191-e18191.	0.8	1
95	Real-world demographic and clinical characteristics of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) in the United States (US).. Journal of Clinical Oncology, 2019, 37, e18347-e18347.	0.8	0
96	Real-world treatment patterns among patients (pts) diagnosed with primary mediastinal large B-cell lymphoma (PMBCL) in the United States (US).. Journal of Clinical Oncology, 2019, 37, e19050-e19050.	0.8	0
97	Healthcare Resource Utilization and Costs in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A U.S. Real-World Observational Study. Blood, 2019, 134, 2133-2133.	0.6	0
98	Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States. Blood, 2019, 134, 4720-4720.	0.6	0
99	Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida. Current Medical Research and Opinion, 2018, 34, 1099-1115.	0.9	4
100	Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 257-265.	0.2	39
101	Factors associated with the number and size of renal angiomyolipomas in sporadic angiomyolipoma (sAML): a study of adult patients with sAML managed in a Dutch tertiary referral center. International Urology and Nephrology, 2018, 50, 459-467.	0.6	10
102	Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis. Current Medical Research and Opinion, 2018, 34, 1261-1269.	0.9	8
103	Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets. Current Medical Research and Opinion, 2018, 34, 1959-1966.	0.9	7
104	Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting. Clinical Genitourinary Cancer, 2018, 16, 50-57.	0.9	19
105	Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma. Melanoma Research, 2018, 28, 618-628.	0.6	23
106	2459. Meningococcal ACWY (MenACWY) Vaccination of Adolescents in the United States: How Compliant Are We With the Advisory Committee on Immunization Practices (ACIP) Recommendations?. Open Forum Infectious Diseases, 2018, 5, S737-S737.	0.4	0
107	Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause, 2018, 25, 1297-1305.	0.8	21
108	Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal angiomyolipoma treated with everolimus. PLoS ONE, 2018, 13, e0204646.	1.1	10

#	ARTICLE	IF	CITATIONS
109	Health characteristics of patients with asthma, COPD and asthma–COPD overlap in the NHANES database. International Journal of COPD, 2018, Volume 13, 2859-2868.	0.9	27
110	Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 500.e1-500.e9.	0.8	41
111	Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication. BMC Infectious Diseases, 2018, 18, 438.	1.3	8
112	Removal of ineligible outcome cases reduces confounding. Clinical Epidemiology, 2018, Volume 10, 575-579.	1.5	1
113	Burden of disease associated with a COPD eosinophilic phenotype. International Journal of COPD, 2018, Volume 13, 2425-2433.	0.9	19
114	Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: Meta-analysis of pivotal trials. Epilepsy Research, 2018, 143, 120-129.	0.8	25
115	Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib+trametinib versus nivolumab or pembrolizumab monotherapy. Current Medical Research and Opinion, 2018, 34, 2169-2176.	0.9	5
116	Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data. Cardiovascular Diabetology, 2018, 17, 118.	2.7	30
117	Hepatitis A, B, and A/B vaccination series completion among US adults: A claims-based analysis. Human Vaccines and Immunotherapeutics, 2018, 14, 1-6.	1.4	11
118	Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among breast cancer patients.. Journal of Clinical Oncology, 2018, 36, e13624-e13624.	0.8	2
119	Time to first-line (1L) therapy discontinuation in metastatic melanoma (MM).. Journal of Clinical Oncology, 2018, 36, 196-196.	0.8	0
120	Real-world analysis of treatment patterns and persistence of octreotide LAR and other agents in patients with advanced gastrointestinal neuroendocrine tumors (GI NET): A multicenter study.. Journal of Clinical Oncology, 2018, 36, 424-424.	0.8	0
121	Comparison of the real-world adherence and compliance patterns with trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 666-666.	0.8	0
122	Improvement of carcinoid syndrome (CS) symptoms and quality of life (QoL) in CS patients treated with somatostatin analogs (SSAs): Results from longitudinal patient surveys.. Journal of Clinical Oncology, 2018, 36, 400-400.	0.8	0
123	Real-world adherence in patients with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI) or regorafenib (REG).. Journal of Clinical Oncology, 2018, 36, 11-11.	0.8	0
124	Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices. Leukemia and Lymphoma, 2017, 58, 1968-1972.	0.6	3
125	Maintenance of weight loss or stability in subjects with obesity: a retrospective longitudinal analysis of a real-world population. Current Medical Research and Opinion, 2017, 33, 1105-1110.	0.9	19
126	Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices. Medical Oncology, 2017, 34, 88.	1.2	6

#	ARTICLE	IF	CITATIONS
127	Assessment of treatment patterns and healthcare costs associated with probable Lennox-Gastaut syndrome. <i>Epilepsy and Behavior</i> , 2017, 73, 46-50.	0.9	24
128	Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors. <i>BMC Endocrine Disorders</i> , 2017, 17, 32.	0.9	4
129	Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. <i>Cancer</i> , 2017, 123, 2875-2880.	2.0	79
130	Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States. <i>Epilepsia</i> , 2017, 58, 1742-1748.	2.6	9
131	Out-of-pocket medical costs and third-party healthcare costs for children with Down syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 627-637.	0.7	23
132	Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting. <i>Medical Oncology</i> , 2017, 34, 160.	1.2	11
133	Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA. <i>Medical Oncology</i> , 2017, 34, 193.	1.2	25
134	Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse. <i>Clinical Therapeutics</i> , 2017, 39, 1380-1395.e4.	1.1	21
135	Burden of systemic glucocorticoid-related complications in severe asthma. <i>Current Medical Research and Opinion</i> , 2017, 33, 57-65.	0.9	53
136	A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy. <i>International Journal of COPD</i> , 2017, Volume 12, 1825-1836.	0.9	13
137	Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) chemotherapy (CT) vs alternative androgen receptor-targeted agents (ARTA) after lack of response to first-line (1L) ARTA in US community oncology practices.. <i>Journal of Clinical Oncology</i> , 2017, 35, 214-214.	0.8	2
138	Association between duration of somatostatin analogs (SSAs) use and quality of life in patients with carcinoid syndrome in the United States based on the FACT-G instrument.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15693-e15693.	0.8	0
139	Real-world adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, e15000-e15000.	0.8	0
140	A Retrospective Chart Review to Assess Burden of Illness Among Patients with Severe Aplastic Anemia with Insufficient Response to Immunosuppressive Therapy. <i>Blood</i> , 2017, 130, 678-678.	0.6	2
141	Dose-Response Relationship Between Long-Term Systemic Corticosteroid Use and Related Complications in Patients with Severe Asthma. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 833-847.	0.5	70
142	MP286NATURAL HISTORY FOR ADULT PATIENTS WITH SPORADIC ANGIOMYOLIPOMA IN THE NETHERLANDS. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i434-i434.	0.4	1
143	Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 1204-1214.	0.5	6
144	Characteristics of Treatment-Experienced HIV-1-Infected Patients Switching from Multi-Tablet to Single-Tablet Regimens in the Veterans Affairs Health Care System. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0

#	ARTICLE	IF	CITATIONS
145	Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims Data. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1067-1075.	1.5	16
146	Real-world glyceimic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozinâ€”an electronic health-record-based study. <i>Current Medical Research and Opinion</i> , 2016, 32, 1151-1159.	0.9	17
147	An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From USÂCommunity Oncology Practices. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 625-636.e3.	0.2	32
148	Can social media data lead to earlier detection of drugâ€related adverse events?. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1425-1433.	0.9	50
149	Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population. <i>Reproductive Health</i> , 2016, 13, 96.	1.2	7
150	Development and validation of an algorithm for identifying urinary retention in a cohort of patients with epilepsy in a large US administrative claims database. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 413-421.	0.9	1
151	Rotavirus vaccination in a Medicaid infant population from four US states: compliance, vaccination completion rate, and predictors of compliance. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1235-1243.	1.4	7
152	Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia. <i>Journal of Medical Economics</i> , 2016, 19, 292-303.	1.0	27
153	Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics. <i>Current Medical Research and Opinion</i> , 2016, 32, 759-769.	0.9	11
154	Improvements in Patient Health-Related Quality of Life (HRQoL) with Clinical Efficacy in Patients Treated with Eltrombopag: Final Results from the Long-Term, Open-Label Extend Study. <i>Blood</i> , 2016, 128, 3742-3742.	0.6	3
155	Public Health Impact of Complete and Incomplete Rotavirus Vaccination among Commercially and Medicaid Insured Children in the United States. <i>PLoS ONE</i> , 2016, 11, e0145977.	1.1	13
156	Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans with Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1332-e1341.	1.1	24
157	Impact of symptomatic skeletal events on healthcare resource utilization, health-related quality of life and pain among patients with castration-resistant prostate cancer and bone metastases.. <i>Journal of Clinical Oncology</i> , 2016, 34, 247-247.	0.8	0
158	Value of Transfusion Independence in Severe Aplastic Anemia from Patients' Perspectives - a Discrete Choice Experiment. <i>Blood</i> , 2016, 128, 5077-5077.	0.6	0
159	A Meta-Analysis and Meta-Regression of the Efficacy of Front-Line Treatment Combinations with Ponatinib Versus 1st- and 2nd-Generation Tyrosine Kinase Inhibitors for Ph+ Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 5189-5189.	0.6	0
160	Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia. <i>American Health and Drug Benefits</i> , 2016, 9, 399-410.	0.5	7
161	Kidney involvement in tuberous sclerosis complex: the impact on healthcare resource use and costs. <i>Journal of Medical Economics</i> , 2015, 18, 1060-1070.	1.0	31
162	Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment. <i>Pharmacoeconomics</i> , 2015, 33, 1049-1067.	1.7	3

#	ARTICLE	IF	CITATIONS
163	Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 378-389.	0.5	41
164	Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 579-592.	0.6	25
165	Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis. <i>Journal of Medical Economics</i> , 2015, 18, 711-720.	1.0	47
166	Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting. <i>Current Medical Research and Opinion</i> , 2015, 31, 1561-1572.	0.9	26
167	Response to Comment on "The Addition of Vasodilators to Loop Diuretics of Value in the Care of Hospitalized Acute Heart Failure Patients? Real-World Evidence From a Retrospective Analysis of a Large United States Hospital Database". <i>Journal of Cardiac Failure</i> , 2015, 21, 435.	0.7	0
168	The epidemiology of herpes zoster and its complications in Medicare cancer patients. <i>BMC Infectious Diseases</i> , 2015, 15, 106.	1.3	37
169	A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments. <i>BMC Cancer</i> , 2015, 15, 175.	1.1	24
170	Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1488-1495.	1.5	162
171	Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy. <i>Leukemia and Lymphoma</i> , 2015, 56, 2803-2811.	0.6	3
172	Age-Related Emergency Department Reliance in Patients with Sickle Cell Disease. <i>Journal of Emergency Medicine</i> , 2015, 49, 513-522.e1.	0.3	56
173	Multicenter COMPACT study of COMplications in Patients with sickle cell disease And utilization of iron Chelation Therapy. <i>Current Medical Research and Opinion</i> , 2015, 31, 513-523.	0.9	9
174	Epidemiologic and Clinical Characteristics of Thalassemia (Thal) Intermedia (TI) in the United States. <i>Blood</i> , 2015, 126, 3279-3279.	0.6	1
175	Clinical features and overall survival (OS) in patients (pts) with post-docetaxel (DTX) metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) therapy in the community setting.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16029-e16029.	0.8	0
176	Association between duration of treatment (DOT) and healthcare costs in multiple myeloma (MM) patients receiving initial therapy with bortezomib.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17792-e17792.	0.8	0
177	The evolving treatment patterns in multiple myeloma (MM): Retrospective database analyses of U.S. community oncology electronic medical records and administrative claims.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17791-e17791.	0.8	0
178	Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer (mCRC) treated with ziv-aflibercept (Z) in community oncology practices in the United States (US).. <i>Journal of Clinical Oncology</i> , 2015, 33, e14554-e14554.	0.8	0
179	Assessing the prognostic impact of intermediate outcomes on survival time in relapsed/refractory multiple myeloma (RRMM) patients (pts) via a robust and clinically interpretable quantitative procedure.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17743-e17743.	0.8	0
180	Treatment patterns and characteristics of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11502-e11502.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Clinical Benefits of Above-Standard Dose of Octreotide LAR in Patients With Neuroendocrine Tumors for Control of Carcinoid Syndrome Symptoms: A Multicenter Retrospective Chart Review Study. <i>Oncologist</i> , 2014, 19, 930-936.	1.9	96
182	Pulse pressure and stroke risk: development and validation of a new stroke risk model. <i>Current Medical Research and Opinion</i> , 2014, 30, 2453-2460.	0.9	13
183	Is Addition of Vasodilators to Loop Diuretics of Value in the Care of Hospitalized Acute Heart Failure Patients? Real-World Evidence From a Retrospective Analysis of a Large United States Hospital Database. <i>Journal of Cardiac Failure</i> , 2014, 20, 853-863.	0.7	6
184	Meta-Analysis of the Efficacy and Safety of Bortezomib Re-Treatment in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 380-388.	0.2	38
185	Subcutaneous (SQ) Bortezomib (BTZ) in Patients (Pts) with Relapsed Mantle Cell Lymphoma (MCL): Retrospective, Observational Study of Treatment Patterns and Outcomes in US Community Oncology Practices. <i>Blood</i> , 2014, 124, 1740-1740.	0.6	1
186	Identifying Motor, Emotional-Behavioral, and Cognitive Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives. <i>Tremor and Other Hyperkinetic Movements</i> , 2014, 4, 224.	1.1	24
187	HD-PRO-TRIADâ„¢ Validation: A Patient-reported Instrument for the Symptom Triad of Huntington's Disease. <i>Tremor and Other Hyperkinetic Movements</i> , 2014, 4, 223.	1.1	13
188	Retrospective analysis of treatment patterns and outcomes with subcutaneous (SQ) bortezomib (BTZ) in patients (pts) with relapsed mantle cell lymphoma (MCL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8554-8554.	0.8	0
189	Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population. <i>Sarcoma</i> , 2013, 2013, 1-13.	0.7	3
190	Drug treatment (tx) patterns and survival among patients (pts) with metastatic or recurrent soft tissue sarcoma (m/rSTS) refractory to at least one prior therapy.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10061-10061.	0.8	0
191	Meta-Analysis of the Efficacy and Safety of Bortezomib Retreatment in Patients with Multiple Myeloma (MM). <i>Blood</i> , 2012, 120, 1863-1863.	0.6	1
192	Abstract 62: Impact of Once-Daily vs. Twice-Daily Dosing Frequency on Adherence in Chronic Medications among Patients with Non-Valvular Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, .	0.9	0
193	Treatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costs. <i>Respiratory Medicine</i> , 2011, 105, 435-441.	1.3	240
194	Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data. <i>Annals of Pharmacotherapy</i> , 2011, 45, 179-188.	0.9	7
195	Abstract P2: Medical Resource Utilization and Costs Following Hospitalization of Patients with Chronic Heart Failure in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, .	0.9	0
196	Age-Related Blood Transfusion Patterns in Patients with Sickle Cell Disease (SCD) and the Association with Sickle Cell Complications. <i>Blood</i> , 2011, 118, 12-12.	0.6	3
197	Age-Related Iron Chelation Utilization and Healthcare Costs in Patients with Sickle Cell Disease (SCD). <i>Blood</i> , 2011, 118, 338-338.	0.6	0
198	Abstract P116: Hospitalization Due to Heart Failure is Associated With Significant Medical Resource Utilization and Costs. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, .	0.9	0

#	ARTICLE	IF	CITATIONS
199	Abstract P84: Antithrombotic Treatment Patterns, Hospitalizations, and Associated Costs in Acute Coronary Syndrome (ACS) Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, .	0.9	0
200	Abstract P105: A Single-Center Experience with Low-Dose Warfarin in Patients Undergoing Total Hip or Total Knee Replacement Surgery. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, .	0.9	0
201	Risk of Hepatotoxicity-Related Hospitalizations among Patients Treated with Opioid/Acetaminophen Combination Prescription Pain Medications. <i>Pain Medicine</i> , 2010, 11, 1718-1725.	0.9	13
202	The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2317-2328.	0.9	21
203	Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis*. <i>Current Medical Research and Opinion</i> , 2009, 25, 2081-2090.	0.9	28
204	Costs associated with cardiovascular events in patients with hypertension in US managed care settings. <i>Journal of the American Society of Hypertension</i> , 2009, 3, 403-415.	2.3	13
205	The Cost-Effectiveness of Bortezomib for the Initial Treatment of Multiple Myeloma in the United States.. <i>Blood</i> , 2009, 114, 1379-1379.	0.6	0
206	Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.. <i>Blood</i> , 2009, 114, 3293-3293.	0.6	1
207	Persistence and Compliance of Deferoxamine Versus Deferasirox in Medicaid Patients with Sickle-Cell Disease.. <i>Blood</i> , 2009, 114, 1982-1982.	0.6	0
208	Impact of compliance with proton pump inhibitors on NSAID treatment. <i>American Journal of Managed Care</i> , 2009, 15, 681-8.	0.8	10
209	Anaemia and the Risk of Injurious Falls in a Community-Dwelling Elderly Population. <i>Drugs and Aging</i> , 2008, 25, 325-334.	1.3	42
210	Management of Anaemia. <i>Pharmacoeconomics</i> , 2008, 26, 99-120.	1.7	19
211	Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis. <i>Current Medical Research and Opinion</i> , 2008, 24, 967-974.	0.9	23
212	Comparison of Infection-Related Hospitalization Risk and Associated Costs among Patients Receiving Sargramostim (Leukine®), Filgrastim (Neupogen®), and Pegfilgrastim (Neulasta®) for Chemotherapy-Induced Neutropenia. <i>Blood</i> , 2008, 112, 665-665.	0.6	2
213	An Economic Evaluation of Bortezomib-Based Induction Therapy in Double Transplant Protocols for Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2008, 112, 2386-2386.	0.6	0
214	Higher Erythroid Response Rates with Epoetin Alfa Versus Other Agents in Treatment-Naïve Low/Int-1 Myelodysplastic Syndrome Patients: A Comparative Meta-Analysis. <i>Blood</i> , 2008, 112, 5074-5074.	0.6	9
215	The Economic Consequences of Generic Substitution for Antiepileptic Drugs in a Public Payer Setting: The Case of Lamotrigine. <i>Disease Management: DM</i> , 2007, 10, 216-225.	1.0	35
216	Dosing Patterns and Treatment Costs of Erythropoietic Agents in Elderly Patients with Pre-Dialysis Chronic Kidney Disease in Managed Care Organisations. <i>Drugs and Aging</i> , 2006, 23, 969-976.	1.3	10

#	ARTICLE	IF	CITATIONS
217	Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. <i>Clinical Therapeutics</i> , 2006, 28, 1443-1450.	1.1	17
218	Impact and treatment of anemia in the elderly: clinical, epidemiological and economic perspectives. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2006, 6, 577-590.	0.7	7
219	Cost-effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy-related anemia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 383-394.	0.7	2
220	Assessing the Clinical Benefits of Erythropoietic Agents Using Area Under the Hemoglobin Change Curve. <i>Oncologist</i> , 2005, 10, 438-448.	1.9	19